Factors associated with seroimmunity against tick borne encephalitis virus 10 years after booster vaccination

• Published in: Vaccine Vol. 31; no. 9; pp. 1293 - 1297
• Main Authors: Paulke-Korinek, Maria, Kundi, Michael, Laaber, Brigitte, Brodtraeger, Natascha, Seidl-Friedrich, Claudia, Wiedermann, Ursula, Kollaritsch, Herwig
• Format: Journal Article
• Language: English
• Published: Kidlington Elsevier Ltd 18.02.2013; Elsevier; Elsevier Limited
• Subjects: Adolescent; Adult; adults; Age; Age Factors; Aged; Allergies; Allergy and Immunology; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Antibody persistence; antigens; Applied microbiology; Arachnids; Arboviral encephalitis; Arboviroses; Biological and medical sciences; Booster properties; Encephalitis; Encephalitis Viruses, Tick-Borne - immunology; Female; Fever; Follow-up; Fundamental and applied biological sciences. Psychology; Human viral diseases; Humans; hypersensitivity; Immune system; immunity; Immunization schedule; Immunologic Memory; Infectious diseases; Ixodidae; Long-term; Male; Medical sciences; Microbiology; Middle Aged; Miscellaneous; neutralization; neutralization tests; Population; secondary immunization; Studies; Tick borne encephalitis; ticks; Time Factors; Tropical viral diseases; Vaccination - methods; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Viral diseases; Viral infections; Viral Vaccines - administration & dosage; Viral Vaccines - immunology; Virology; viruses; Young Adult; Austria; Europe; Booster properties; Long-term; Antibody persistence; Tick borne encephalitis; Immunization schedule; Follow-up; Nervous system diseases; Immunization; Antibody; Booster vaccination; Vaccine; Flavivirus; Cerebral disorder; Infection; Tick borne encephalitis group virus; Virus; Viral disease; Arbovirus disease; Central nervous system disease; Flaviviridae; Tick borne encephalitis virus

► Tick borne encephalitis antibody titers were assessed in 178 and 183 subjects 8 and 10 years post-booster. ► Cumulative seroprotection rates were 86.8% and 77.3% 8 and 10 years post-booster. ► Antibody levels were significantly lower in subjects starting at the age of 50 years. ► Antibody levels w...